327- Melmed GY, Targan SR. In: Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F,
Wang TC, editors. Crohn’s disease: clinical manifestations and management, in Yamada’s atlas
of gastroenterology. Oxford: John Wiley & Sons, Ltd; 2016. - Peyrin-Biroulet L, et al. Selecting therapeutic targets in inflammatory Bowel dis-
ease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol.
2015;110(9):1324–38. - Melmed GY, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable
illnesses. Am J Gastroenterol. 2006;101(8):1834–40. - Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care
in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58. PubMed PMID:
28071656. - Bennett NM, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumo-
coccal polysaccharide vaccine for adults with immunocompromising conditions: recommen-
dations of the advisory committee on immunization practices (ACIP) (reprinted from MMWR
vol 40, pg 816, 2012). JAMA. 2013;309(4):334–6. - Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompro-
mised host. Clin Infect Dis. 2014;58(3):309–18. - Sands BE, et al. Guidelines for immunizations in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 2004;10(5):677–92. - Cekic C, et al. Evaluation of factors associated with response to hepatitis B vaccination in
patients with inflammatory bowel disease. Medicine (Baltimore). 2015;94(22):e940. - Dezfoli S, Melmed GY. Vaccination issues in patients with inflammatory bowel disease receiv-
ing immunosuppression. Gastroenterol Hepatol (N Y). 2012;8(8):504–12. - Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immuno-
modulators and biologics. Inflamm Bowel Dis. 2009;15(9):1410–6. - Sanchez-Tembleque MD, Corella C, Perez-Calle JL. Vaccines and recommendations for their
use in inflammatory bowel disease. World J Gastroenterol. 2013;19(9):1354–8. - Wyant T, et al. Vedolizumab affects antibody responses to immunisation selectively in the
gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83. - Brodmerkel C, et al. Immune response to pneumococcus and tetanus toxoid in patients
with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol.
2013;12(10):1122–9. - Cush JJ, Yazici Y. Laboratory monitoring of biologic therapies. Clin Exp Rheumatol.
2005;23(5):S90–2. - Hanson RL, et al. Improvement in safety monitoring of biologic response modifiers
after the implementation of clinical care guidelines by a specialty. J Manag Care Pharm.
2013;19(1):49–67. - Bonovas S, et al. Biologic therapies and risk of infection and malignancy in patients with inflam-
matory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol
Hepatol. 2016;14(10):1385–1397.e10. - Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol
Ther. 2009;22(5):418–30. - Kotlyar DS, et al. A systematic review of factors that contribute to hepatosplenic T-cell lym-
phoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–
41.e1. - Long MD, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflam-
matory bowel disease. Gastroenterology. 2012;143(2):390. - Benchimol EI, et al. Incidence, outcomes, and health services burden of very early onset
inflammatory bowel disease. Gastroenterology. 2014;147(4):803–U156. - Cottone M, et al. Advanced age is an independent risk factor for severe infections and mortal-
ity in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin
Gastroenterol Hepatol. 2011;9(1):30–5. - Colombel JF, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo
clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31.
18 Quality, Safety, and Practical Considerations of Using Biologic Therapies